Jim Simons Viracta Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 245,399 shares of VIRX stock, worth $61,349. This represents 0.0% of its overall portfolio holdings.

Number of Shares

245,399

Previous 217,699 12.72%

Holding current value

$61,349

Previous $117,000 52.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.21 - $0.56 $5,817 - $15,512	27,700 Added 12.72%	245,399 $56,000
Q2 2024 Aug 09, 2024	BUY	$0.5 - $1.17 $7,600 - $17,784	15,200 Added 7.51%	217,699 $117,000
Q1 2024 May 13, 2024	BUY	$0.48 - $1.13 $11,328 - $26,667	23,600 Added 13.19%	202,499 $207,000
Q4 2023 Feb 13, 2024	BUY	$0.44 - $1.04 $13,508 - $31,928	30,700 Added 20.72%	178,899 $102,000
Q3 2023 Nov 14, 2023	BUY	$1.03 - $1.58 $13,802 - $21,172	13,400 Added 9.94%	148,199 $154,000
Q2 2023 Aug 11, 2023	BUY	$0.89 - $2.13 $8,455 - $20,235	9,500 Added 7.58%	134,799 $190,000
Q1 2023 May 12, 2023	SELL	$1.38 - $2.29 $19,993 - $33,177	-14,488 Reduced 10.36%	125,299 $199,000
Q4 2022 Feb 13, 2023	BUY	$1.26 - $4.38 $55,298 - $192,229	43,888 Added 45.76%	139,787 $204,000
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $8,300 - $14,225	2,500 Added 2.68%	95,899 $409,000
Q2 2022 Aug 12, 2022	BUY	$1.87 - $5.0 $84,896 - $226,995	45,399 Added 94.58%	93,399 $362,000
Q1 2022 May 13, 2022	SELL	$2.23 - $4.76 $150,971 - $322,252	-67,700 Reduced 58.51%	48,000 $228,000
Q4 2021 Feb 11, 2022	BUY	$3.37 - $7.91 $389,909 - $915,187	115,700 New	115,700 $422,000

Others Institutions Holding VIRX

# of Institutions

Shares Held

5.63M

Call Options Held

Put Options Held

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account